Crispin Blunt MP joins Psych Capital
Psych Capital Plc is pleased to announce the appointment of the Conservative Drug Policy Reform Group (CDPRG) representative, Crispin Blunt MP, to its Medical Psychedelic Technical Advisory Board.
Since Psych Capital’s IPO, the board has been reviewing the regulatory landscape and investment opportunities in the UK, Europe and further afield, including drug development and patient delivery pathways.
It has been actively working with the CDPRG as part of its existing advisory agreement with them.
The expertise of the CDPRG in identifying regulatory barriers and opportunities, patient need, healthcare delivery frameworks, and political landscapes, has been instrumental as Psych Capital assesses a number of opportunities for strategic deployment of capital, leveraging its position as the first listed psychedelic company in London.READ MORE